These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28863391)

  • 1. A precision medicine approach for psychiatric disease based on repeated symptom scores.
    Fojo AT; Musliner KL; Zandi PP; Zeger SL
    J Psychiatr Res; 2017 Dec; 95():147-155. PubMed ID: 28863391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
    Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
    Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
    Hopkins SC; Ogirala A; Loebel A; Koblan KS
    Schizophr Bull; 2018 Apr; 44(3):593-602. PubMed ID: 28981857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: meta-analysis.
    Takeuchi H; Kantor N; Sanches M; Fervaha G; Agid O; Remington G
    Br J Psychiatry; 2017 Sep; 211(3):137-143. PubMed ID: 28522434
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach.
    Lipkovich IA; Deberdt W; Csernansky JG; Buckley P; Peuskens J; Kollack-Walker S; Rotelli M; Houston JP
    Psychiatry Res; 2009 Dec; 170(2-3):161-7. PubMed ID: 19897252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia.
    Lenert LA; Rupnow MF; Elnitsky C
    Health Qual Life Outcomes; 2005 Sep; 3():57. PubMed ID: 16153308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Hierarchical Bayesian Model for Personalized Survival Predictions.
    Bellot A; van der Schaar M
    IEEE J Biomed Health Inform; 2019 Jan; 23(1):72-80. PubMed ID: 29994056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized treatment of schizophrenia in everyday clinical practice: reality or fiction?
    Plesničar BK
    Psychiatr Danub; 2015 Sep; 27(3):314-8. PubMed ID: 26400144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A computational algorithm for personalized medicine in schizophrenia.
    Lee BS; McIntyre RS; Gentle JE; Park NS; Chiriboga DA; Lee Y; Singh S; McPherson MA
    Schizophr Res; 2018 Feb; 192():131-136. PubMed ID: 28495491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.
    Birur B; Thirthalli J; Janakiramaiah N; Shelton RC; Gangadhar BN
    Asian J Psychiatr; 2016 Dec; 24():17-22. PubMed ID: 27931900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis.
    Williams DR; Bürkner PC
    Psychoneuroendocrinology; 2017 Jan; 75():141-151. PubMed ID: 27825069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Selection in Depression.
    Cohen ZD; DeRubeis RJ
    Annu Rev Clin Psychol; 2018 May; 14():209-236. PubMed ID: 29494258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.
    Basu A; Meltzer HY; Dukic V
    Stat Med; 2006 Sep; 25(17):2886-910. PubMed ID: 16220519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating clinical trial data: outcome measures.
    Conley RR
    J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and outcome with antipsychotic drugs.
    Pouget JG; Shams TA; Tiwari AK; Müller DJ
    Dialogues Clin Neurosci; 2014 Dec; 16(4):555-66. PubMed ID: 25733959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Rank Precision of Population Health Measures for Small Areas with Longitudinal and Joint Outcome Models.
    Athens JK; Remington PL; Gangnon RE
    PLoS One; 2015; 10(6):e0130027. PubMed ID: 26098858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.